HONG KONG – The CFDA approved the Roche Group's Actemra (tocilizumab), which targets systemic juvenile idiopathic arthritis (sJIA). The approval marks the entry of the first biologic in the Chinese market for the disease and could lower a long-standing reliance on corticosteroids to deal with the pain of joint inflammation among children.
HONG KONG – The CFDA approved the Roche Group's Actemra (tocilizumab), which targets systemic juvenile idiopathic arthritis (sJIA). The approval marks the entry of the first biologic in the Chinese market for the disease and could lower a long-standing reliance on corticosteroids to deal with the pain of joint inflammation among children.
HONG KONG – In yet another of a growing list of acquisitions, Chinese drugmaker Luye Pharma Group Ltd. (2186.HK) has inked an agreement to acquire Swiss-based Acino Holdings AG's transdermal drug delivery systems (TDS) business.
HONG KONG – In yet another of a growing list of acquisitions, Chinese drugmaker Luye Pharma Group Ltd. (2186.HK) has inked an agreement to acquire Swiss-based Acino Holdings’ transdermal drug delivery systems (TDS) business.
HONG KONG – Chinese pharmaceutical companies in areas around the capital of Beijing are expecting to take a hit to their bottom lines for an unusual reason: pollution. Drug manufacturers in the province that neighbors Beijing were ordered to "temporarily" halt operations to address severe smog in the capital.
HONG KONG – Chinese pharmaceutical companies in areas around the capital of Beijing are expecting to take a hit to their bottom lines for an unusual reason: pollution. Drug manufacturers in the province that neighbors Beijing were ordered to “temporarily” halt operations to address severe smog in the capital.
